BR112018011278A2 - tratamento de degeneração da retina com o uso de células progenitoras - Google Patents

tratamento de degeneração da retina com o uso de células progenitoras

Info

Publication number
BR112018011278A2
BR112018011278A2 BR112018011278A BR112018011278A BR112018011278A2 BR 112018011278 A2 BR112018011278 A2 BR 112018011278A2 BR 112018011278 A BR112018011278 A BR 112018011278A BR 112018011278 A BR112018011278 A BR 112018011278A BR 112018011278 A2 BR112018011278 A2 BR 112018011278A2
Authority
BR
Brazil
Prior art keywords
cells
progenitor cells
retinal degeneration
retinal
degeneration treatment
Prior art date
Application number
BR112018011278A
Other languages
English (en)
Inventor
Harris Ian
Cao Jing
Sophia DEJNEKA Nadine
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112018011278A2 publication Critical patent/BR112018011278A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

a presente invenção refere-se a métodos e composições para tratar e reduzir a degeneração retiniana com o uso de células progenitoras e meio condicionado de células progenitoras, como células derivadas do pós-parto. também são revelados fatores genéticos e receptores expressos pelas células progenitoras que auxiliam na proteção de células retinianas e na inibição de apoptose de células retinianas, como células fotorreceptoras.
BR112018011278A 2015-12-04 2016-12-01 tratamento de degeneração da retina com o uso de células progenitoras BR112018011278A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562263463P 2015-12-04 2015-12-04
PCT/US2016/064336 WO2017095991A1 (en) 2015-12-04 2016-12-01 Treatment of retinal degeneration using progenitor cells

Publications (1)

Publication Number Publication Date
BR112018011278A2 true BR112018011278A2 (pt) 2018-11-21

Family

ID=58797699

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011278A BR112018011278A2 (pt) 2015-12-04 2016-12-01 tratamento de degeneração da retina com o uso de células progenitoras

Country Status (15)

Country Link
US (1) US20170157179A1 (pt)
EP (1) EP3384009A4 (pt)
JP (1) JP2019501888A (pt)
KR (1) KR20180088713A (pt)
CN (1) CN108291199A (pt)
AR (1) AR106913A1 (pt)
AU (1) AU2016365312A1 (pt)
BR (1) BR112018011278A2 (pt)
CA (1) CA3007198A1 (pt)
MX (1) MX2018006729A (pt)
PH (1) PH12018501045A1 (pt)
RU (1) RU2018122461A (pt)
SG (1) SG11201803781XA (pt)
TW (1) TW201729819A (pt)
WO (1) WO2017095991A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
KR102224115B1 (ko) 2020-01-10 2021-03-09 경북대학교병원 3차원 바이오프린팅 기술을 이용한 망막 세포 배양용 구조체 및 이의 활용

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001855A (en) * 1998-01-02 1999-12-14 Hoffman-La Roche Inc. Thiazole derivatives
US20010041670A1 (en) * 1999-12-06 2001-11-15 Ronit Simantov Thrombospondin-binding region of histidine-rich glycoprotein and method of use
JP2005504757A (ja) * 2001-08-01 2005-02-17 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 眼の疾患の治療用インテグリン阻害剤
JP5148873B2 (ja) * 2003-06-27 2013-02-20 エチコン、インコーポレイテッド 臍帯組織由来の分娩後細胞、及びその作成及び使用方法
US8790637B2 (en) * 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
WO2009064448A1 (en) * 2007-11-15 2009-05-22 The Feinstein Institute For Medical Research Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8
ES2820855T3 (es) * 2011-05-09 2021-04-22 Allegro Pharmaceuticals Llc Antagonistas del receptor de integrina y sus métodos de uso
US20150150996A1 (en) * 2012-06-06 2015-06-04 Northwestern University Compositions and methods for antigen-specific tolerance
RU2017124983A (ru) * 2014-12-16 2019-01-17 Янссен Байотек, Инк. Лечение дегенерации сетчатки с использованием клеток-предшественников

Also Published As

Publication number Publication date
PH12018501045A1 (en) 2019-01-28
EP3384009A1 (en) 2018-10-10
AR106913A1 (es) 2018-02-28
CN108291199A (zh) 2018-07-17
SG11201803781XA (en) 2018-06-28
EP3384009A4 (en) 2019-06-12
RU2018122461A (ru) 2020-01-13
TW201729819A (zh) 2017-09-01
AU2016365312A1 (en) 2018-05-24
JP2019501888A (ja) 2019-01-24
MX2018006729A (es) 2018-11-09
CA3007198A1 (en) 2017-06-08
US20170157179A1 (en) 2017-06-08
KR20180088713A (ko) 2018-08-06
WO2017095991A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
BR112017012581A2 (pt) tratamento de degeneração da retina com o uso de células progenitoras
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MD20170035A2 (ro) Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
PH12015501648B1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
EP3598980A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
EP3342858A4 (en) ROR1-POSITIVE MESENCHYMAL STEM CELLS AND PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREOF, AND METHOD FOR PREVENTING OR TREATING DISEASES USING SAID ROR1 POSITIVE MESENCHYMAL STEM CELLS
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
MX2017001103A (es) Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
ZA201703467B (en) Methods of treating ocular conditions
BR112016017817A2 (pt) composições e métodos para o tratamento e a prevenção de degeneração macular
MX2018005312A (es) Composiciones y metodos para el tratamiento de la homocistinuria.
BR112018011278A2 (pt) tratamento de degeneração da retina com o uso de células progenitoras
PH12017501601A1 (en) Use of isolated fractions of mastic gum for treating optic neuropathy
PH12018502704A1 (en) Treatment of retinal vascular disease using progenitor cells
BR112017011513A2 (pt) tratamento de condições oculares usando células progenitoras
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
BR112016019893A2 (pt) composições de glicoproteína sialilada e seus usos
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
AU2016349439A8 (en) Non-bioconvertible C3-substituted pregnenolone derivatives for use in the treatment of substance use disorders

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]